A Prospective Study of Combination of Anti-PD-1 Plus Autologous DC-CIK Cell Immunotherapy and Hyperthermia for Patients With Advanced Malignant Mesothelioma
Latest Information Update: 09 Feb 2024
At a glance
- Drugs Pembrolizumab (Primary) ; Dendritic cell-activated cytokine-induced killer cells
- Indications Malignant-mesothelioma
- Focus Therapeutic Use
- 05 Feb 2024 Status changed from recruiting to discontinued.
- 14 Jul 2020 Planned End Date changed from 1 Dec 2020 to 30 Jun 2022.
- 14 Jul 2020 Planned primary completion date changed from 1 Jun 2020 to 31 Dec 2021.